Pedro Marques Ramos

865 total citations
18 papers, 557 citations indexed

About

Pedro Marques Ramos is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Pedro Marques Ramos has authored 18 papers receiving a total of 557 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 6 papers in Genetics and 5 papers in Oncology. Recurrent topics in Pedro Marques Ramos's work include Acute Myeloid Leukemia Research (9 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers) and Acute Lymphoblastic Leukemia research (4 papers). Pedro Marques Ramos is often cited by papers focused on Acute Myeloid Leukemia Research (9 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers) and Acute Lymphoblastic Leukemia research (4 papers). Pedro Marques Ramos collaborates with scholars based in Switzerland, United States and Germany. Pedro Marques Ramos's co-authors include Mohamed Bentires‐Alj, Pierre Fenaux, Uwe Platzbecker, Amit Verma, Karen Cornille, Cédric Leroy, Christine Fritsch, Hans Voshol, Débora Bonenfant and Michael Dickinson and has published in prestigious journals such as The Journal of Experimental Medicine, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Pedro Marques Ramos

18 papers receiving 553 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pedro Marques Ramos Switzerland	9	251	184	161	93	90	18	557
Tai‐Chung Huang Taiwan	16	376 1.5×	172 0.9×	154 1.0×	68 0.7×	173 1.9×	39	761
Krysta Schlis United States	4	405 1.6×	101 0.5×	182 1.1×	68 0.7×	67 0.7×	6	625
Vincent Romanet Switzerland	10	334 1.3×	107 0.6×	174 1.1×	134 1.4×	55 0.6×	13	513
Andrea Ghelli Luserna di Rorà Italy	13	513 2.0×	115 0.6×	303 1.9×	63 0.7×	98 1.1×	38	735
Yunxiang Zhang China	15	200 0.8×	79 0.4×	200 1.2×	42 0.5×	121 1.3×	42	554
Zhihong Zeng United States	6	467 1.9×	203 1.1×	111 0.7×	119 1.3×	43 0.5×	13	652
Orsi Giricz United States	11	347 1.4×	104 0.6×	172 1.1×	36 0.4×	125 1.4×	23	567
Maria Nyåkern Italy	7	426 1.7×	173 0.9×	82 0.5×	55 0.6×	62 0.7×	11	585
Luigia Rao Italy	8	227 0.9×	179 1.0×	158 1.0×	38 0.4×	68 0.8×	10	390
Stanley Ng Canada	8	527 2.1×	353 1.9×	124 0.8×	50 0.5×	157 1.7×	19	782

Countries citing papers authored by Pedro Marques Ramos

Since Specialization

Citations

This map shows the geographic impact of Pedro Marques Ramos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pedro Marques Ramos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pedro Marques Ramos more than expected).

Fields of papers citing papers by Pedro Marques Ramos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pedro Marques Ramos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pedro Marques Ramos. The network helps show where Pedro Marques Ramos may publish in the future.

Co-authorship network of co-authors of Pedro Marques Ramos

This figure shows the co-authorship network connecting the top 25 collaborators of Pedro Marques Ramos. A scholar is included among the top collaborators of Pedro Marques Ramos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pedro Marques Ramos. Pedro Marques Ramos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Zeidan, Amer M., Pierre Fenaux, Xia Han, et al.. (2023). Molecular Measurable Residual Disease (MRD) Clearance (≤1%) Is Associated with Improved Clinical Outcomes in Patients with Higher-Risk Myelodysplastic Neoplasms (HR-MDS): An Exploratory Analysis of Stimulus-MDS1 in Patients Receiving Sabatolimab or Placebo + Hypomethylating Agent (HMA). Blood. 142(Supplement 1). 3236–3236. 3 indexed citations

Zeidan, Amer M., Kiyoshi Ando, Odile Beyne Rauzy, et al.. (2023). Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Haematology. 11(1). e38–e50. 36 indexed citations

Schmidt, Sara A., et al.. (2023). An examination of the reliability of seed-to-seed resting state functional connectivity in tinnitus patients. SHILAP Revista de lepidopterología. 3(1). 100158–100158. 1 indexed citations

Okoye-Okafor, Ujunwa Cynthia, Komal Kumar Javarappa, Joseph Saad, et al.. (2022). Megakaryopoiesis impairment through acute innate immune signaling activation by azacitidine. The Journal of Experimental Medicine. 219(11). 1 indexed citations

Santini, Valeria, Uwe Platzbecker, Pierre Fenaux, et al.. (2022). Disease Characteristics and International Prognostic Scoring Systems (IPSS, IPSS-R, IPSS-M) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Participating in Two Randomized, Double-Blind, Placebo-Controlled Studies with Intravenous Sabatolimab Added to Hypomethylating Agents (HMA) (STIMULUS-MDS1 and MDS2). Blood. 140(Supplement 1). 1340–1342. 4 indexed citations

Zeidan, Amer M., Amy E. DeZern, Uma Borate, et al.. (2022). Stimulus MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very High-Risk Myelodysplastic Syndrome (MDS). Blood. 140(Supplement 1). 4069–4070. 1 indexed citations

Zeidan, Amer M., Kiyoshi Ando, Odile Beyne Rauzy, et al.. (2022). Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS). Blood. 140(Supplement 1). 2063–2065. 11 indexed citations

Brück, Oscar, Helena Hohtari, Aleksandr Ianevski, et al.. (2021). Machine Learning of Bone Marrow Histopathology Identifies Genetic and Clinical Determinants in Patients with MDS. Blood Cancer Discovery. 2(3). 238–249. 36 indexed citations

Zeidan, Amer M., Amy E. DeZern, Uma Borate, et al.. (2021). MDS-364: STIMULUS MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very High–Risk Myelodysplastic Syndromes (MDS). Clinical Lymphoma Myeloma & Leukemia. 21. S348–S349. 1 indexed citations

10.

Ramos, Pedro Marques, Priska Auf der Maur, Atul Sethi, et al.. (2021). The NFIB‐ERO1A axis promotes breast cancer metastatic colonization of disseminated tumour cells. EMBO Molecular Medicine. 13(4). e13162–e13162. 33 indexed citations

11.

Brück, Oscar, Olli Dufva, Helena Hohtari, et al.. (2020). Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival. Blood Advances. 4(2). 274–286. 44 indexed citations

12.

Husain, Fatima T., et al.. (2019). Replicability of Neural and Behavioral Measures of Tinnitus Handicap in Civilian and Military Populations: Preliminary Results. American Journal of Audiology. 28(1S). 191–208. 4 indexed citations

13.

Chen, Jiahao, Swathi-Rao Narayanagari, Tihomira I. Todorova, et al.. (2018). Thrombopoietin receptor–independent stimulation of hematopoietic stem cells by eltrombopag. Science Translational Medicine. 10(458). 45 indexed citations

14.

Dickinson, Michael, Honar Cherif, Pierre Fenaux, et al.. (2018). Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. Blood. 132(25). 2629–2638. 66 indexed citations

15.

Benard, Lumie, Luis A. Carvajal, Amit Verma, et al.. (2017). Pre-Clinical Modeling of Concomitant Therapy with Azacytidine and Eltrombopag in MDS/AML. Blood. 130. 2950. 3 indexed citations

16.

Leroy, Cédric, Pedro Marques Ramos, Karen Cornille, et al.. (2016). Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition. Breast Cancer Research. 18(1). 41–41. 60 indexed citations

17.

Casu, Carla, Paraskevi Rea Oikonomidou, Mariam Aghajan, et al.. (2016). Potential Therapeutic Applications of Jak2 Inhibitors and Hif2a-ASO for the Treatment of β-Thalassemia Intermedia and Major. Blood. 128(22). 1012–1012. 3 indexed citations

18.

Ramos, Pedro Marques & Mohamed Bentires‐Alj. (2014). Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene. 34(28). 3617–3626. 205 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact